Search

Your search keyword '"Oak, Jean"' showing total 208 results
Start Over Author "Oak, Jean"
208 results on '"Oak, Jean"'

3. CD22-directed CAR T-cell therapy for large B-cell lymphomas progressing after CD19-directed CAR T-cell therapy: a dose-finding phase 1 study

Author

Klysz, Dorota Danuta, Gkitsas-Long, Nikolaos, Bacigalupi, Juliana, Iglesias, Maria, Crawford, Emma, Nichols, Linnea, Cunanan, Kristen, Tamaresis, John, Spiegel, Jay Y., Ehlinger, Zachary, Kuo, Adam, Reynolds, Warren D., Arai, Sally, Johnston, Laura, Lowsky, Robert, Meyer, Everett, Negrin, Robert S., Rezvani, Andrew R., Shiraz, Parveen, Sidana, Surbhi, Weng, Wen Kai, Bharadwaj, Sushma, Dahiya, Saurabh, Smith, Melody, Schultz, Liora M., Ramakrishna, Sneha, Davis, Kara L., Tunuguntla, Ramya, Frank, Matthew J, Baird, John H, Kramer, Anne Marijn, Srinagesh, Hrishikesh K, Patel, Shabnum, Brown, Annie Kathleen, Oak, Jean S, Younes, Sheren F, Natkunam, Yasodha, Hamilton, Mark P, Su, Yi-Jiun, Agarwal, Neha, Chinnasamy, Harshini, Egeler, Emily, Mavroukakis, Sharon, Feldman, Steven A, Sahaf, Bita, Mackall, Crystal L, Muffly, Lori, and Miklos, David B

Published
2024
Full Text
View/download PDF

4. Detection of cryptogenic malignancies from metagenomic whole genome sequencing of body fluids

Author

Gu, Wei, Talevich, Eric, Hsu, Elaine, Qi, Zhongxia, Urisman, Anatoly, Federman, Scot, Gopez, Allan, Arevalo, Shaun, Gottschall, Marc, Liao, Linda, Tung, Jack, Chen, Lei, Lim, Harumi, Ho, Chandler, Kasowski, Maya, Oak, Jean, Holmes, Brittany J, Yeh, Iwei, Yu, Jingwei, Wang, Linlin, Miller, Steve, DeRisi, Joseph L, Prakash, Sonam, Simko, Jeff, and Chiu, Charles Y

Subjects
Rare Diseases, Human Genome, Cancer, Genetics, Lung, Clinical Research, 4.2 Evaluation of markers and technologies, 4.1 Discovery and preclinical testing of markers and technologies, Detection, screening and diagnosis, Infection, Good Health and Well Being, Body Fluids, Case-Control Studies, Computational Biology, Cytogenetic Analysis, Disease Management, Disease Susceptibility, Flow Cytometry, Histocytochemistry, Humans, In Situ Hybridization, Fluorescence, Liquid Biopsy, Metagenome, Metagenomics, Neoplasms, Reproducibility of Results, Sensitivity and Specificity, Clinical Sciences
Abstract

BackgroundMetagenomic next-generation sequencing (mNGS) of body fluids is an emerging approach to identify occult pathogens in undiagnosed patients. We hypothesized that metagenomic testing can be simultaneously used to detect malignant neoplasms in addition to infectious pathogens.MethodsFrom two independent studies (n = 205), we used human data generated from a metagenomic sequencing pipeline to simultaneously screen for malignancies by copy number variation (CNV) detection. In the first case-control study, we analyzed body fluid samples (n = 124) from patients with a clinical diagnosis of either malignancy (positive cases, n = 65) or infection (negative controls, n = 59). In a second verification cohort, we analyzed a series of consecutive cases (n = 81) sent to cytology for malignancy workup that included malignant positives (n = 32), negatives (n = 18), or cases with an unclear gold standard (n = 31).ResultsThe overall CNV test sensitivity across all studies was 87% (55 of 63) in patients with malignancies confirmed by conventional cytology and/or flow cytometry testing and 68% (23 of 34) in patients who were ultimately diagnosed with cancer but negative by conventional testing. Specificity was 100% (95% CI 95-100%) with no false positives detected in 77 negative controls. In one example, a patient hospitalized with an unknown pulmonary illness had non-diagnostic lung biopsies, while CNVs implicating a malignancy were detectable from bronchoalveolar fluid.ConclusionsMetagenomic sequencing of body fluids can be used to identify undetected malignant neoplasms through copy number variation detection. This study illustrates the potential clinical utility of a single metagenomic test to uncover the cause of undiagnosed acute illnesses due to cancer or infection using the same specimen.

Published
2021

5. p53 immunohistochemistry as an ancillary tool for rapid assessment of residual disease in TP53-mutated acute myeloid leukemia and myelodysplastic syndromes.

Author

Brar, Nivaz, Lawrence, Lauren, Fung, Eula, Zehnder, James L, Greenberg, Peter L, Mannis, Gabriel N, Zhang, Tian Y, Gratzinger, Dita, Oak, Jean, Silva, Oscar, Kurzer, Jason, Tan, Brent, Menke, Joshua R, and Fernandez-Pol, Sebastian

Subjects
ACUTE myeloid leukemia, BONE marrow cells, MYELODYSPLASTIC syndromes, MYELOID cells, BONE marrow
Abstract

Objectives Measurable residual disease flow cytometry (MRD-FC) and molecular studies are the most sensitive methods for detecting residual malignant populations after therapy for TP53 -mutated acute myeloid leukemia and myelodysplastic neoplasms (TP53+ AML/MDS). However, their sensitivity is limited in suboptimal aspirates or when the immunophenotype of the neoplastic blasts overlaps with erythroids or normal maturing myeloid cells. In this study, we set out to determine if p53 immunohistochemistry (IHC) correlates with MRD-FC and next-generation sequencing (NGS) in the posttherapy setting and to determine the utility of p53 IHC to detect residual disease in the setting of negative or equivocal MRD-FC. Methods We retrospectively identified 28 pre- and posttherapy bone marrow biopsy specimens from 9 patients with TP53+ AML/MDS and a p53 overexpressor phenotype by IHC (strong 3+ staining at initial diagnosis). Next-generation sequencing and/or MRD-FC results were collected for each specimen. Results Using a threshold of more than ten 2-3+ cells in any one 400× field, p53 IHC detected residual disease with a sensitivity of 94% and a specificity of 89%. The threshold used in this study showed a high degree of concordance among 6 blinded pathologists (Fleiss κ = 0.97). Conclusions Our study suggests that p53 IHC can be used as a rapid tool (within 24 hours) to aid in the detection of residual disease that may complement MRD-FC or NGS in cases in which the flow cytometry immunophenotype is equivocal and/or the bone marrow aspirate is suboptimal. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

6. Prevalence and clinicopathological features of incidentally detected TRBC1-dim populations in peripheral blood flow cytometry.

Author

Wadsworth, Paul, Zhang, Jingjing, Miller, Timothy, Menke, Joshua, Oak, Jean, and Fernandez-Pol, Sebastian

Subjects
MUCOSA-associated lymphoid tissue lymphoma, CHRONIC myeloid leukemia, CHRONIC lymphocytic leukemia, OLDER patients, HEMATOLOGIC malignancies, LYMPHADENITIS
Abstract

This document is a letter to the editor published in the journal Leukemia & Lymphoma. The authors conducted a retrospective analysis to understand the nature of TRBC1-dim populations, which are T-cell clones of uncertain significance (T-CUS), detected in peripheral blood samples. They aimed to estimate the prevalence of these populations, document their immunophenotypic features, and document the clinical characteristics of patients with these populations. The study found that 6.7% of samples and 6.1% of patients had TRBC1-dim populations, with the average age of patients with these populations being 70 years. The authors concluded that these populations are unlikely to represent a circulating T-cell neoplasm and are more likely to be a recurrent artifact. [Extracted from the article]

Published
2024
Full Text
View/download PDF

7. CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial

Author

Spiegel, Jay Y., Patel, Shabnum, Muffly, Lori, Hossain, Nasheed M., Oak, Jean, Baird, John H., and Frank, Matthew J.

Subjects
Antineoplastic agents -- Dosage and administration -- Testing, Lymphomas -- Care and treatment -- Diagnosis -- Development and progression, Antimitotic agents -- Dosage and administration -- Testing, Biological sciences, Health
Abstract

Despite impressive progress, more than 50% of patients treated with CD19-targeting chimeric antigen receptor T cells (CAR19) experience progressive disease. Ten of 16 patients with large B cell lymphoma (LBCL) with progressive disease after CAR19 treatment had absent or low CD19. Lower surface CD19 density pretreatment was associated with progressive disease. To prevent relapse with CD19.sup.- or CD19.sup.lo disease, we tested a bispecific CAR targeting CD19 and/or CD22 (CD19-22.BB.z-CAR) in a phase I clinical trial (NCT03233854) of adults with relapsed/refractory B cell acute lymphoblastic leukemia (B-ALL) and LBCL. The primary end points were manufacturing feasibility and safety with a secondary efficacy end point. Primary end points were met; 97% of products met protocol-specified dose and no dose-limiting toxicities occurred during dose escalation. In B-ALL (n = 17), 100% of patients responded with 88% minimal residual disease-negative complete remission (CR); in LBCL (n = 21), 62% of patients responded with 29% CR. Relapses were CD19.sup.-/lo in 50% (5 out of 10) of patients with B-ALL and 29% (4 out of 14) of patients with LBCL but were not associated with CD22.sup.-/lo disease. CD19/22-CAR products demonstrated reduced cytokine production when stimulated with CD22 versus CD19. Our results further implicate antigen loss as a major cause of CAR T cell resistance, highlight the challenge of engineering multi-specific CAR T cells with equivalent potency across targets and identify cytokine production as an important quality indicator for CAR T cell potency. Bispecific CAR T cells targeting CD19 and CD22 exhibit clinical activity and low toxicity in patients with large B cell lymphoma and B cell acute lymphoblastic leukemia, with relapses associated with loss of CD19 but not CD22., Author(s): Jay Y. Spiegel [sup.1] , Shabnum Patel [sup.2] , Lori Muffly [sup.1] [sup.2] , Nasheed M. Hossain [sup.3] , Jean Oak [sup.4] , John H. Baird [sup.1] , Matthew [...]

Published
2021
Full Text
View/download PDF

8. CD19 Antigen Density Down-Regulation at Time of Progression in Large B-Cell Lymphoma Patients Treated with Axicabtagene Ciloleucel

Author

Spiegel, Jay, primary, Oak, Jean S., additional, Goyal, Anmol, additional, Bornheimer, Scott, additional, Irvine, Allison, additional, Shen, Rhine R., additional, Kong, Katherine A., additional, Bharadwaj, Sushma, additional, Weng, Wen-Kai, additional, Smith, Melody, additional, Frank, Matthew J., additional, Dahiya, Saurabh, additional, and Miklos, David B., additional

Published
2024
Full Text
View/download PDF

10. Multiplexed single-cell morphometry for hematopathology diagnostics

Author

Tsai, Albert G., Glass, David R., Juntilla, Marisa, Hartmann, Felix J., Oak, Jean S., Fernandez-Pol, Sebastian, and Ohgami, Robert S.

Subjects
Oncology, Experimental, Lymphomas -- Diagnosis, Hematopoietic stem cells -- Identification and classification -- Properties, Morphometrics (Biology) -- Research, Cancer -- Research, Biological sciences, Health
Abstract

The diagnosis of lymphomas and leukemias requires hematopathologists to integrate microscopically visible cellular morphology with antibody-identified cell surface molecule expression. To merge these into one high-throughput, highly multiplexed, single-cell assay, we quantify cell morphological features by their underlying, antibody-measurable molecular components, which empowers mass cytometers to 'see' like pathologists. When applied to 71 diverse clinical samples, single-cell morphometric profiling reveals robust and distinct patterns of 'morphometric' markers for each major cell type. Individually, lamin B1 highlights acute leukemias, lamin A/C helps distinguish normal from neoplastic mature T cells, and VAMP-7 recapitulates light-cytometric side scatter. Combined with machine learning, morphometric markers form intuitive visualizations of normal and neoplastic cellular distribution and differentiation. When recalibrated for myelomonocytic blast enumeration, this approach is superior to flow cytometry and comparable to expert microscopy, bypassing years of specialized training. The contextualization of traditional surface markers on independent morphometric frameworks permits more sensitive and automated diagnosis of complex hematopoietic diseases. A scalable mass cytometry-based method for morphometrically classifying hematopoietic cells demonstrates diagnostic utility when applied to clinical samples., Author(s): Albert G. Tsai [sup.1] , David R. Glass [sup.1] [sup.2] , Marisa Juntilla [sup.1] , Felix J. Hartmann [sup.1] , Jean S. Oak [sup.1] , Sebastian Fernandez-Pol [sup.1] , [...]

Published
2020
Full Text
View/download PDF

11. CD22-directed CAR T-cell therapy for large B-cell lymphomas progressing after CD19-directed CAR T-cell therapy: a dose-finding phase 1 study

Author

Frank, Matthew J, Baird, John H, Kramer, Anne Marijn, Srinagesh, Hrishikesh K, Patel, Shabnum, Brown, Annie Kathleen, Oak, Jean S, Younes, Sheren F, Natkunam, Yasodha, Hamilton, Mark P, Su, Yi-Jiun, Agarwal, Neha, Chinnasamy, Harshini, Egeler, Emily, Mavroukakis, Sharon, Feldman, Steven A, Sahaf, Bita, Mackall, Crystal L, Muffly, Lori, Miklos, David B, Klysz, Dorota Danuta, Gkitsas-Long, Nikolaos, Bacigalupi, Juliana, Iglesias, Maria, Crawford, Emma, Nichols, Linnea, Cunanan, Kristen, Tamaresis, John, Spiegel, Jay Y., Ehlinger, Zachary, Kuo, Adam, Reynolds, Warren D., Arai, Sally, Johnston, Laura, Lowsky, Robert, Meyer, Everett, Negrin, Robert S., Rezvani, Andrew R., Shiraz, Parveen, Sidana, Surbhi, Weng, Wen Kai, Bharadwaj, Sushma, Dahiya, Saurabh, Smith, Melody, Schultz, Liora M., Ramakrishna, Sneha, Davis, Kara L., and Tunuguntla, Ramya

Abstract

Outcomes are poor for patients with large B-cell lymphoma who relapse after CD19-directed chimeric antigen receptor (CAR) T-cell therapy (CAR19). CD22 is a nearly universally expressed B-cell surface antigen and the efficacy of a CD22-directed CAR T-cell therapy (CAR22) in large B-cell lymphoma is unknown, which was what we aimed to examine in this study.

Published
2024
Full Text
View/download PDF

16. Epstein–Barr virus-induced gene 3 negatively regulates neuroinflammation and T cell activation following coronavirus-induced encephalomyelitis

Author

Tirotta, Emanuele, Duncker, Patrick, Oak, Jean, Klaus, Suzi, Tsukamoto, Michelle R, Gov, Lanny, and Lane, Thomas E

Subjects
Infectious Diseases, Genetics, HIV/AIDS, Aetiology, 2.2 Factors relating to the physical environment, 2.1 Biological and endogenous factors, Infection, Good Health and Well Being, Animals, Antigens, CD, CD8 Antigens, Coronavirus Infections, Cytokines, Disease Models, Animal, Encephalomyelitis, Flow Cytometry, Gene Expression Regulation, Viral, Glial Fibrillary Acidic Protein, Interferon-gamma, Interleukin-10, Lymphocyte Activation, Mice, Mice, Inbred C57BL, Mice, Knockout, Minor Histocompatibility Antigens, RNA, Messenger, Receptors, Cytokine, T-Lymphocytes, Time Factors, Virus, Neuroinflammation, Demyelination, Immunology, Neurosciences, Neurology & Neurosurgery
Abstract

Epstein-Barr virus-induced gene 3 (EBI3) associates with p28 and p35 to form the immunomodulatory cytokines IL-27 and IL-35, respectively. Infection of EBI3-/- mice with the neuroadapted JHM strain of mouse hepatitis virus (JHMV) resulted in increased mortality that was not associated with impaired ability to control viral replication but enhanced T cell and macrophage infiltration into the CNS. IFN-γ secretion from virus-specific CD4+ and CD8+ T cells isolated from infected EBI3-/- mice was augmented while IL-10 expression muted in comparison to infected WT mice. These data demonstrate a regulatory role for EBI3-associated cytokines in controlling host responses following CNS viral infection.

Published
2013

17. Selective Inhibition of Phosphoinositide 3-Kinase p110? Preserves Lymphocyte Function*

Author

So, Lomon, Yea, Sung Su, Oak, Jean S., Lu, Mengrou, Manmadhan, Arun, Ke, Qiao Han, Janes, Matthew R., Kessler, Linda V., Kucharski, Jeff M., Li, Lian-Sheng, Martin, Michael B., Ren, Pingda, Jessen, Katti A., Liu, Yi, Rommel, Christian, and Fruman, David A.

Abstract

Background: The class IA PI3K isoform p110α is a promising drug target in cancer therapy yet its role in lymphocytes is not known.Results: Lymphocyte function was minimally affected by p110α inhibition both in vitro and in vivo.Conclusion: Selective inhibition of p110α preserves lymphocyte function.Significance: The study raises confidence that selective p110α inhibitors in cancer therapy will not be immunosuppressive.Class IA phosphoinositide 3-kinase (PI3K) is essential for clonal expansion, differentiation, and effector function of B and T lymphocytes. The p110δ catalytic isoform of PI3K is highly expressed in lymphocytes and plays a prominent role in B and T cell responses. Another class IA PI3K catalytic isoform, p110α, is a promising drug target in cancer but little is known about its function in lymphocytes. Here we used highly selective inhibitors to probe the function of p110α in lymphocyte responses in vitro and in vivo. p110α inhibition partially reduced B cell receptor (BCR)-dependent AKT activation and proliferation, and diminished survival supported by the cytokines BAFF and IL-4. Selective p110δ inhibition suppressed B cell responses much more strongly, yet maximal suppression was achieved by targeting multiple PI3K isoforms. In mouse and human T cells, inhibition of single class IA isoforms had little effect on proliferation, whereas pan-class I inhibition did suppress T cell expansion. In mice, selective p110α inhibition using the investigational agent MLN1117 (previously known as INK1117) did not disrupt the marginal zone B cell compartment and did not block T cell-dependent germinal center formation. In contrast, the selective p110δ inhibitor IC87114 strongly suppressed germinal center formation and reduced marginal zone B cell numbers, similar to a pan-class I inhibitor. These findings show that although acute p110α inhibition partially diminishes AKT activation, selective p110α inhibitors are likely to be less immunosuppressive in vivo compared with p110δ or pan-class I inhibitors.

Published
2012

19. S230: CD22 CAR T CELL THERAPY IS SAFE AND EFFECTIVE IN PATIENTS WITH LARGE B CELL LYMPHOMA WHO HAVE RELAPSED AFTER CD19 CAR T CELL THERAPY.

Author

Frank, Matthew J., primary, Baird, John, additional, Kramer, Anne, additional, Patel, Shabnum, additional, Sahaf, Bita, additional, Craig, Juliana, additional, Crawford, Emma, additional, Younes, Sheren, additional, Oak, Jean, additional, Natkunan, Yasodha, additional, Spiegel, Jay, additional, Ehlinger, Zachary, additional, Chinnasamy, Harshini, additional, Reynolds, Warren, additional, Srinagesh, Hrishi, additional, Su, Yi-Jiun, additional, Egeler, Emily, additional, Feldman, Steven, additional, Mackall, Crystal, additional, Muffly, Lori, additional, and Miklos, David, additional

Published
2023
Full Text
View/download PDF

20. TRBC1in flow cytometry: Assay development, validation, and reporting considerations

Author

Devitt, Katherine A., Kern, Wolfgang, Li, Weijie, Wang, Xuehai, Wong, Allyson J., Furtado, Felipe M., Oak, Jean S., and Illingworth, Andrea

Abstract

The assessment of T‐cell clonality by flow cytometry has long been suboptimal, relying on aberrant marker expression and/or intensity. The introduction of TRBC1 shows much promise for improving the diagnosis of T‐cell neoplasms in the clinical flow laboratory. Most laboratories considering this marker already have existing panels designed for T‐cell workups and will be determining how best to incorporate TRBC1. We present this comprehensive summary of TRBC1 and supplemental case examples to familiarize the flow cytometry community with its potential for routine application, provide examples of how to incorporate it into T‐cell panels, and signal caution in interpreting the results in certain diagnostic scenarios where appropriate.

Published
2024
Full Text
View/download PDF

21. Oligomonocytic chronic myelomonocytic leukemia (chronic myelomonocytic leukemia without absolute monocytosis) displays a similar clinicopathologic and mutational profile to classical chronic myelomonocytic leukemia

Author

Geyer, Julia T, Tam, Wayne, Liu, Yen-Chun, Chen, Zhengming, Wang, Sa A, Bueso-Ramos, Carlos, Oak, Jean, Arber, Daniel A, Hsi, Eric, Rogers, Heesun J, Levinson, Katherine, Bagg, Adam, Hassane, Duane C, Hasserjian, Robert P, and Orazi, Attilio

Published
2017
Full Text
View/download PDF

24. CD22 CAR T Cell Therapy Induces Durable Remissions in Patients with Large B Cell Lymphoma Who Relapse after CD19 CAR T Cell Therapy

Author

Frank, Matthew J., primary, Sahaf, Bita, additional, Baird, John, additional, Patel, Shabnum, additional, Craig, Juliana, additional, Iglesias, Maria, additional, Crawford, Emma, additional, Oak, Jean S., additional, Younes, Sheren F., additional, Natkunam, Yasodha, additional, Srinagesh, Hrishikesh K., additional, Spiegel, Jay, additional, Ehlinger, Zachary, additional, Chinnasamy, Harshini, additional, Reynolds, Warren D., additional, Egeler, Emily, additional, Arai, Sally, additional, Johnston, Laura, additional, Lowsky, Robert, additional, Negrin, Robert S., additional, Rezvani, Andrew R., additional, Shiraz, Parveen, additional, Sidana, Surbhi, additional, Weng, Wen-Kai, additional, Dahiya, Saurabh, additional, Smith, Melody, additional, Schultz, Liora Michal, additional, Ramakrishna, Sneha, additional, Davis, Kara L, additional, Feldman, Steven, additional, Mackall, Crystal, additional, Muffly, Lori, additional, and Miklos, David B., additional

Published
2023
Full Text
View/download PDF

25. Role of peripheral blood MRD and 18F-FDG PET in the post-CAR relapse setting: a case study of discordant peripheral blood and bone marrow MRD

Author

Schultz, Liora, primary, Davis, Kara Lynn, additional, Walkush, Ann, additional, Baggott, Christina, additional, Erickson, Courtney, additional, Ramakrishna, Sneha, additional, Aftandilian, Catherine, additional, Lacayo, Norman, additional, Nadel, Helen Ruth, additional, Oak, Jean, additional, and Mackall, Crystal L, additional

Published
2023
Full Text
View/download PDF

26. Determinants of resistance to engineered T cell therapies targeting CD19 in large B cell lymphomas

Author

Sworder, Brian J., primary, Kurtz, David M., additional, Alig, Stefan K., additional, Frank, Matthew J., additional, Shukla, Navika, additional, Garofalo, Andrea, additional, Macaulay, Charles W., additional, Shahrokh Esfahani, Mohammad, additional, Olsen, Mari N., additional, Hamilton, James, additional, Hosoya, Hitomi, additional, Hamilton, Mark, additional, Spiegel, Jay Y., additional, Baird, John H., additional, Sugio, Takeshi, additional, Carleton, Mia, additional, Craig, Alexander F.M., additional, Younes, Sheren F., additional, Sahaf, Bita, additional, Sheybani, Natasha D., additional, Schroers-Martin, Joseph G., additional, Liu, Chih Long, additional, Oak, Jean S., additional, Jin, Michael C., additional, Beygi, Sara, additional, Hüttmann, Andreas, additional, Hanoun, Christine, additional, Dührsen, Ulrich, additional, Westin, Jason R., additional, Khodadoust, Michael S., additional, Natkunam, Yasodha, additional, Majzner, Robbie G., additional, Mackall, Crystal L., additional, Diehn, Maximilian, additional, Miklos, David B., additional, and Alizadeh, Ash A., additional

Published
2023
Full Text
View/download PDF

28. Determinants of Resistance to Engineered T-Cell Therapies Targeting CD19 in Large B-Cell Lymphomas

Author

Sworder, Brian, primary, Kurtz, David M., additional, Alig, Stefan K., additional, Frank, Matthew J, additional, Shukla, Navika D., additional, Garofalo, Andrea, additional, Macaulay, Charles, additional, Shahrokh Esfahani, Mohammad, additional, Olsen, Mari, additional, Hamilton, James, additional, Hosoya, Hitomi, additional, Hamilton, Mark P, additional, Spiegel, Jay Y., additional, Baird, John H., additional, Carleton, Mia, additional, Craig, Alexander F.M., additional, Younes, Sheren F., additional, Sahaf, Bita, additional, Sheybani, Natasha, additional, Schroers-Martin, Joseph, additional, Liu, Chih Long, additional, Oak, Jean S, additional, Jin, Michael C., additional, Beygi, Sara, additional, Hüttmann, Andreas, additional, Hanoun, Christine, additional, Dührsen, Ulrich, additional, Westin, Jason, additional, Khodadoust, Michael S., additional, Natkunam, Yasodha, additional, Majzner, Robbie G., additional, Mackall, Crystal L., additional, Diehn, Maximilian, additional, Miklos, David B., additional, and Alizadeh, Ash A., additional

Published
2022
Full Text
View/download PDF

30. Targeted Mutational Profiling Reveals Clonal Relationships in Metachronous Occurrence of Classic Hodgkin and Mediastinal Large B-Cell Lymphomas

Author

Singh, Kunwar, primary, Lezama, Lhara S., additional, Kurzer, Jason, additional, Oak, Jean, additional, Schultz, Liora M., additional, Walkush, Ann, additional, Cheng, Tse-Chang, additional, Chen, Everett H., additional, May, William A., additional, Chang, Cheryl, additional, Link, Michael P., additional, Advani, Ranjana H., additional, Suarez, Carlos J., additional, and Natkunam, Yasodha, additional

Published
2022
Full Text
View/download PDF

31. Circulating lobular breast carcinoma cells.

Author

Tan, Brent and Oak, Jean

Subjects
*FLOW cytometry, *BIOPSY, *CANCER invasiveness, *BLOOD testing, *BREAST tumors, *BLOOD cell count, *LOBULAR carcinoma, *SEQUENCE analysis
Abstract

The article focuses on the identification of circulating lobular breast carcinoma cells through peripheral blood smear analysis and advanced diagnostic techniques. Topics include the characterization of atypical cells via flow cytometry, the implications of genetic mutations like DNMT3a R882H, and differential diagnoses such as hematologic neoplasms and plasma cell disorders.

Published
2024
Full Text
View/download PDF

32. Proinflammatory Cytokines are Associated with CAR-22 Macrophage Activation Syndrome

Author

Srinagesh, Hrishikesh K., primary, Baird, John, additional, Patel, Shabnum, additional, Reschke, Agnes, additional, Craig, Juliana, additional, Spiegel, Jay, additional, Bharadwaj, Sushma, additional, Ehlinger, Zachary, additional, Chinnasamy, Harshini, additional, Younes, Sheren F., additional, Oak, Jean S., additional, Natkunam, Yasodha, additional, Reynolds, Warren D., additional, Iglesias, Maria, additional, Crawford, Emma, additional, Egeler, Emily, additional, Schultz, Liora Michal, additional, Ramakrishna, Sneha, additional, Davis, Kara L, additional, Sahaf, Bita, additional, Feldman, Steven, additional, Mackall, Crystal, additional, Miklos, David B., additional, Muffly, Lori, additional, and Frank, Matthew J., additional

Published
2022
Full Text
View/download PDF

35. CD22-CAR T-Cell Therapy Mediates High Durable Remission Rates in Adults with Large B-Cell Lymphoma Who Have Relapsed after CD19-CAR T-Cell Therapy

Author

Frank, Matthew J., primary, Baird, John H., additional, Patel, Shabnum, additional, Craig, Juliana, additional, Spiegel, Jay Y., additional, Ehlinger, Zachary, additional, Chinnasamy, Harshini, additional, Younes, Sheren F., additional, Oak, Jean S., additional, Natkunam, Yasodha, additional, Reynolds, Warren D., additional, Iglesias, Maria, additional, Crawford, Emma, additional, Srinagesh, Hrishikesh K., additional, Egeler, Emily L., additional, Arai, Sally, additional, Johnston, Laura J., additional, Lowsky, Robert, additional, Negrin, Robert S., additional, Rezvani, Andrew R., additional, Shiraz, Parveen, additional, Sidana, Surbhi, additional, Weng, Wen-Kai, additional, Schultz, Liora M., additional, Ramakrishna, Sneha, additional, Davis, Kara L., additional, Sahaf, Bita, additional, Feldman, Steven A., additional, Mackall, Crystal L., additional, Miklos, David B., additional, and Muffly, Lori, additional

Published
2021
Full Text
View/download PDF

36. Additional file 1 of Detection of cryptogenic malignancies from metagenomic whole genome sequencing of body fluids

Author

Gu, Wei, Talevich, Eric, Hsu, Elaine, Qi, Zhongxia, Urisman, Anatoly, Federman, Scot, Gopez, Allan, Arevalo, Shaun, Gottschall, Marc, Liao, Linda, Tung, Jack, Chen, Lei, Lim, Harumi, Ho, Chandler, Kasowski, Maya, Oak, Jean, Holmes, Brittany J., Yeh, Iwei, Yu, Jingwei, Wang, Linlin, Miller, Steve, DeRisi, Joseph L., Prakash, Sonam, Simko, Jeff, and Chiu, Charles Y.

Abstract

Additional file 1: Supplementary Results.

Published
2021
Full Text
View/download PDF

37. Additional file 6 of Detection of cryptogenic malignancies from metagenomic whole genome sequencing of body fluids

Author

Gu, Wei, Talevich, Eric, Hsu, Elaine, Qi, Zhongxia, Urisman, Anatoly, Federman, Scot, Gopez, Allan, Arevalo, Shaun, Gottschall, Marc, Liao, Linda, Tung, Jack, Chen, Lei, Lim, Harumi, Ho, Chandler, Kasowski, Maya, Oak, Jean, Holmes, Brittany J., Yeh, Iwei, Yu, Jingwei, Wang, Linlin, Miller, Steve, DeRisi, Joseph L., Prakash, Sonam, Simko, Jeff, and Chiu, Charles Y.

Abstract

Additional file 6: Figure S1. Microbiological cases with overlapping features with cancer presentations.

Published
2021
Full Text
View/download PDF

38. CD22-directed CAR T-cell therapy induces complete remissions in CD19-directed CAR–refractory large B-cell lymphoma

Author

Baird, John H., primary, Frank, Matthew J., additional, Craig, Juliana, additional, Patel, Shabnum, additional, Spiegel, Jay Y., additional, Sahaf, Bita, additional, Oak, Jean S., additional, Younes, Sheren F., additional, Ozawa, Michael G., additional, Yang, Eric, additional, Natkunam, Yasodha, additional, Tamaresis, John, additional, Ehlinger, Zachary, additional, Reynolds, Warren D., additional, Arai, Sally, additional, Johnston, Laura, additional, Lowsky, Robert, additional, Meyer, Everett, additional, Negrin, Robert S., additional, Rezvani, Andrew R., additional, Shiraz, Parveen, additional, Sidana, Surbhi, additional, Weng, Wen-Kai, additional, Davis, Kara L., additional, Ramakrishna, Sneha, additional, Schultz, Liora, additional, Mullins, Chelsea, additional, Jacob, Allison, additional, Kirsch, Ilan, additional, Feldman, Steven A., additional, Mackall, Crystal L., additional, Miklos, David B., additional, and Muffly, Lori, additional

Published
2021
Full Text
View/download PDF

39. Anti-CD22 CAR T-Cell Therapy Mediates Durable Complete Responses in Adults with Relapsed or Refractory Large B-Cell Lymphoma after Failure of Anti-CD19 CAR T-Cell Therapy and High Response Rates in Adults with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia

Author

Frank, Matthew J., primary, Baird, John, additional, Craig, Juliana, additional, Patel, Shabnum, additional, Spiegel, Jay, additional, Sahaf, Bita, additional, Younes, Sheren F., additional, Oak, Jean S., additional, Natkunam, Yasodha, additional, Ehlinger, Zachary, additional, Reynolds, Warren D., additional, Arai, Sally, additional, Johnston, Laura, additional, Lowsky, Robert, additional, Negrin, Robert S., additional, Rezvani, Andrew R., additional, Shiraz, Parveen, additional, Sidana, Surbhi, additional, Weng, Wen-Kai, additional, Schultz, Liora, additional, Ramakrishna, Sneha, additional, Davis, Kara L, additional, Feldman, Steven, additional, Mackall, Crystal L, additional, Miklos, David B., additional, and Muffly, Lori, additional

Published
2021
Full Text
View/download PDF

40. 2 - CD22 CAR T Cell Therapy Induces Durable Remissions in Patients with Large B Cell Lymphoma Who Relapse after CD19 CAR T Cell Therapy

Author

Frank, Matthew J., Sahaf, Bita, Baird, John, Patel, Shabnum, Craig, Juliana, Iglesias, Maria, Crawford, Emma, Oak, Jean S., Younes, Sheren F., Natkunam, Yasodha, Srinagesh, Hrishikesh K., Spiegel, Jay, Ehlinger, Zachary, Chinnasamy, Harshini, Reynolds, Warren D., Egeler, Emily, Arai, Sally, Johnston, Laura, Lowsky, Robert, Negrin, Robert S., Rezvani, Andrew R., Shiraz, Parveen, Sidana, Surbhi, Weng, Wen-Kai, Dahiya, Saurabh, Smith, Melody, Schultz, Liora Michal, Ramakrishna, Sneha, Davis, Kara L, Feldman, Steven, Mackall, Crystal, Muffly, Lori, and Miklos, David B.

Published
2023
Full Text
View/download PDF

41. CD22-Directed CAR T-Cell Therapy Mediates Durable Complete Responses in Adults with Relapsed or Refractory Large B-Cell Lymphoma after Failure of CD19-Directed CAR T-Cell Therapy and High Response Rates in Adults with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia

Author

Baird, John H., primary, Frank, Matthew J., additional, Craig, Juliana, additional, Patel, Shabnum, additional, Spiegel, Jay Y., additional, Sahaf, Bita, additional, Younes, Sheren F., additional, Oak, Jean S., additional, Natkunam, Yasodha, additional, Ehlinger, Zachary, additional, Reynolds, Warren D., additional, Arai, Sally, additional, Johnston, Laura J., additional, Lowsky, Robert, additional, Negrin, Robert S., additional, Rezvani, Andrew R., additional, Shiraz, Parveen, additional, Sidana, Surbhi, additional, Weng, Wen-Kai, additional, Schultz, Liora M., additional, Ramakrishna, Sneha, additional, Davis, Kara L, additional, Feldman, Steven A., additional, Mackall, Crystal L., additional, Miklos, David B., additional, and Muffly, Lori S., additional

Published
2020
Full Text
View/download PDF

44. Identification of dual positive CD19+/CD3+ T cells in a leukapheresis product undergoing CAR transduction: a case report

Author

Schultz, Liora, primary, Patel, Shabnum, additional, Davis, Kara Lynn, additional, Ramakrishna, Sneha, additional, Sahaf, Bita, additional, Bhatia, Neehar, additional, Baggott, Christina, additional, Erickson, Courtney, additional, Majzner, Robbie G, additional, Oak, Jean, additional, Bertaina, Alice, additional, Mackall, Crystal, additional, and Feldman, Steven, additional

Published
2020
Full Text
View/download PDF

46. 198 - Proinflammatory Cytokines are Associated with CAR-22 Macrophage Activation Syndrome

Author

Srinagesh, Hrishikesh K., Baird, John, Patel, Shabnum, Reschke, Agnes, Craig, Juliana, Spiegel, Jay, Bharadwaj, Sushma, Ehlinger, Zachary, Chinnasamy, Harshini, Younes, Sheren F., Oak, Jean S., Natkunam, Yasodha, Reynolds, Warren D., Iglesias, Maria, Crawford, Emma, Egeler, Emily, Schultz, Liora Michal, Ramakrishna, Sneha, Davis, Kara L, Sahaf, Bita, Feldman, Steven, Mackall, Crystal, Miklos, David B., Muffly, Lori, and Frank, Matthew J.

Published
2022
Full Text
View/download PDF

47. Identification of Dual Positive CD19+/CD3+ T Cells in an Apheresis Product Undergoing Chimeric Antigen Receptor (CAR) Transduction

Author

Schultz, Liora M, primary, Patel, Shabnum, additional, Ramakrishna, Sneha, additional, Bertaina, Alice, additional, Bhatia, Neehar, additional, Oak, Jean, additional, Majzner, Robbie G., additional, Baggott, Christina, additional, Davis, Kara L., additional, Mackall, Crystal L., additional, and Feldman, Steven A, additional

Published
2019
Full Text
View/download PDF

48. Circulating DNA for Molecular Response Prediction, Characterization of Resistance Mechanisms and Quantification of CAR T-Cells during Axicabtagene Ciloleucel Therapy

Author

Sworder, Brian, primary, Kurtz, David M., primary, Macaulay, Charles, primary, Frank, Matthew J., primary, Alig, Stefan, primary, Garofalo, Andrea, primary, Sahaf, Bita, primary, Esfahani, Mohammad Shahrokh, primary, Spiegel, Jay Y., primary, Oak, Jean, primary, Beygi, Sara, primary, Jin, Michael C., primary, Chabon, Jacob J, primary, Khodadoust, Michael S., primary, Majzner, Robbie G., primary, Mackall, Crystal L., primary, Diehn, Maximilian, primary, Miklos, David B, primary, and Alizadeh, Ash A., primary

Published
2019
Full Text
View/download PDF

50. 79 - Anti-CD22 CAR T-Cell Therapy Mediates Durable Complete Responses in Adults with Relapsed or Refractory Large B-Cell Lymphoma after Failure of Anti-CD19 CAR T-Cell Therapy and High Response Rates in Adults with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia

Author

Frank, Matthew J., Baird, John, Craig, Juliana, Patel, Shabnum, Spiegel, Jay, Sahaf, Bita, Younes, Sheren F., Oak, Jean S., Natkunam, Yasodha, Ehlinger, Zachary, Reynolds, Warren D., Arai, Sally, Johnston, Laura, Lowsky, Robert, Negrin, Robert S., Rezvani, Andrew R., Shiraz, Parveen, Sidana, Surbhi, Weng, Wen-Kai, Schultz, Liora, Ramakrishna, Sneha, Davis, Kara L, Feldman, Steven, Mackall, Crystal L, Miklos, David B., and Muffly, Lori

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results